91759-33-0

Basic information

• Product Name: Acetic acid, [[4-chloro-6-(2,3-dimethylphenoxy)-2-pyrimidinyl]thio]-, ethyl ester
• CAS NO: 91759-33-0
• Molecular Formula: C16H17ClN2O3S
• Molecular Weight: 352.842
• Mol File: 91759-33-0.mol

Chemical Properties

• CAS DataBase Reference: Acetic acid, [[4-chloro-6-(2,3-dimethylphenoxy)-2-pyrimidinyl]thio]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [[4-chloro-6-(2,3-dimethylphenoxy)-2-pyrimidinyl]thio]-, ethyl ester(91759-33-0)
• EPA Substance Registry System: Acetic acid, [[4-chloro-6-(2,3-dimethylphenoxy)-2-pyrimidinyl]thio]-, ethyl ester(91759-33-0)

Safety Data

• Hazardous Substances Data: 91759-33-0(Hazardous Substances Data)

Upstream product

• 526-75-0 2,3-Dimethylphenol 
• 50892-12-1 ethyl <<4,6-dichloro-2-pyrimidinyl>thio>acetate 
• 50892-49-4 ethyl [(4,6-dihydroxypyrimidin-2-yl)-sulfanyl]acetate 

Downstream Products

• 65089-17-0 <<4-chloro-6-<(2,3-dimethylphenyl)amino>-2-pyrimidinyl>thio>-N-(2-hydroxyethyl)acetamide 
• 91759-34-1 <<4-chloro-6--2-pyrimidinyl>thio>-N-(2-hydroxyethyl)acetamide 
• 86627-49-8 ({4-ethoxy-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl}thio)-N-(2-hydroxyethyl)acetamide 
• 86627-11-4 <<4-ethoxy-6-<(2,3-dimethylphenyl)amino>-2-pyrimidinyl>thio>acetic acid 
• 50892-23-4 pirinixic acid 
• 91759-31-8 2-((4-chloro-6-(2,3-dimethylphenoxy)pyrimidin-2-yl)sulfanyl)acetic acid 

Relevant articles and documents

Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation

The fatty acid sensing nuclear receptor families retinoid X receptors (RXRs) and peroxisome proliferator-activated receptors (PPARs) hold therapeutic potential in neurodegeneration. Valuable pleiotropic activities of Wy14,643 in models of such conditions

Novel pyrimidine and 1,3,5-triazine hypolipidemic agents

New compounds were synthesized by changing the substituents of a trisubstituted pyrimidine, i.e., [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid, a potent hypolipidemic agent, impaired, however, by a marked hepatomegaly-inducing effect. The structural variations led to the subsidence (14b, i.e., 4-chloro-2-(dimethylamino)-6-[(2,3-dimethylphenyl)amino]pyrimidine) or to the reduction (18b, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]amino]acetic acid) of said untoward effect but still maintained the hypolipidemic effect that, although markedly decreased, still proves significant for serum cholesterol and triglycerides (18b) or for serum triglycerides only (14b).